Brief: Pharnext Updates On Pivotal Clinical Development Program For Its PXT3003

Pharnext SCA

01/02/2021 17:08

Feb 1 (Reuters) - Pharnext SA  PHARN.PA :
    * PROVIDES AN UPDATE ON ITS PIVOTAL CLINICAL DEVELOPMENT
PROGRAM
FOR ITS LEAD MEDICINE PXT3003 IN CHARCOT-MARIE-TOOTH TYPE 1A
('CMT1A')
    * EXPECTS TO BEGIN FIRST-PATIENT-FIRST-DOSE IN ITS CLINICAL
PIVOTAL PHASE III TRIAL ENTITLED PREMIER BEFORE MARCH 31, 2021
IN U.S.
    * PREMIER TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 350
SUBJECTS
FROM 50 CENTERS WORLDWIDE
    * PHARNEXT HAS ALSO APPLIED FOR, AND IS INTERACTING WITH FDA
REGARDING A SPECIAL PROTOCOL ASSESSMENT ('SPA') FOR PREMIER
PHASE III TRIAL
    * PHARNEXT WILL BE REPORTING TOP-LINE INTERIM DATA ON SAFETY
AND
EFFICACY OF PXT3003 COLLECTED SO FAR FROM THIS OPEN LABEL STUDY
DURING Q2 2021

Source text for Eikon:  ID:nEQ2PH4Ppa 
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))